复旦大学附属华东医院血液科近日在血液领域权威期刊Blood Cancer Journal上在线发表了题为“Decitabine with etoposide is effective in TP53 mutated myeloid tumors via ...

Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for patients with ...